Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify the cost of implementing a performance-based MEA at the hospi...

Full description

Bibliographic Details
Main Authors: Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Journal of Market Access & Health Policy
Subjects:
Value-based agreements
managed entry agreement
patient access scheme
reimbursement
Chimeric Antigen Receptor T-cell therapy
acute lymphoblastic leukaemia
regenerative medicine
outcomes-based
innovative contracting
Online Access:http://dx.doi.org/10.1080/20016689.2018.1511679

Internet

http://dx.doi.org/10.1080/20016689.2018.1511679

Similar Items